An ipilimumab update: the data from San Francisco

Posted on March 9, 2010 by Sitemaster

In June 2009 we reported on data suggesting that the monocolonal antibody ipilimumab appeared to be capable of “downstaging” more advanced forms of prostate cancer such that the patients became re-eligible for localized therapy with curative intent. It’s time for an update based on data presented at the Genitourinary Cancers Symposium last Friday and Saturday.

Filed under: Drugs in development, Management, Treatment | Tagged: , , , | Leave a Comment »

“Prostate cancer, research funding, and male vanity”

Posted on March 9, 2010 by Sitemaster

Stan Goldberg writes a regular column for Examiner.com on “end of life” issues. However, after the Congressional hearing on prostate cancer in Washington, DC, last Thursday, he turned his thoughts to something that is clearly, for him, a little closer to home. It’s worth a read.

Filed under: Uncategorized | Comments Off

Chili pepper product slows PSA doubling time in prostate cancer patient

Posted on March 8, 2010 by Sitemaster

Several years ago (2006 to be precise) it was reported — by Mori et al. and by Sánchez et al. — that capsaicin (the strong-smelling, active component of chili peppers) was able to kill prostate cancer cells in mouse-based cell cultures.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , | 7 Comments »

Prostate cancer risk and first-degree relatives

Posted on March 7, 2010 by Sitemaster

It would be easy to get the impression that there is nothing new on the prostate cancer front except what’s coming out from San Francisco, but here’s some interesting new information from Germany and Sweden.

Filed under: Diagnosis, Risk | Tagged: , , | 2 Comments »

The data behind the $3,400 test for prostate cancer recurrence

Posted on March 6, 2010 by Sitemaster

Some days ago we commented on a media release issued by Myriad Genetics which stated that their new PROLARIS™ test “identifies patients at low risk of disease recurrence with 95% certainty.”

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 5 Comments »

Short-term ADT with RT for localized prostate cancer

Posted on March 6, 2010 by Sitemaster

The RTOG 94-08 clinical trial was designed to test the idea that just 4 months of hormone therapy, administered  before and during radiation therapy, would improved the overall survival of patients diagnosed with clinical stage T1b-T2b prostate cancer and a PSA level equal to or lower than 20 ng/ml.

Filed under: Management, Treatment | Tagged: , , , , | 1 Comment »

The search for better diagnostic tests for prostate cancer

Posted on March 6, 2010 by Sitemaster

Three papers presented on Friday at the Genitourinary Cancers Symposium in San Francisco addressed the near-term development of tests that may be able to improve our ability to accurately diagnose clinically significant prostate cancer.

Filed under: Diagnosis, Risk | Tagged: , , , | Leave a Comment »

Phase III data on early chemohormonal therapy in high-risk patients

Posted on March 5, 2010 by Sitemaster

Results of a study (the GETUG 12 trial) presented today at the ASCO 2010 Genitourinary Cancer Symposium in San Francisco suggest that the addition of docetaxel-based chemotherapy to androgen deprivation and radiation therapy may impact biochemical recurrence of prostate cancer in high risk patients with localized disease — but it will take a while before [...]

Filed under: Uncategorized | Tagged: , , | 1 Comment »

On the pros and cons of screening for prostate cancer

Posted on March 5, 2010 by Sitemaster

A critical session at the GU cancer meeting this morning was designed to address the pros and cons of screening patients for prostate cancer.

Filed under: Diagnosis, Management, Prevention, Risk | Tagged: , , | 5 Comments »

The ASCO Genitourinary Cancer Symposium 2010

Posted on March 5, 2010 by Sitemaster

The ASCO Genitourinary Cancer Symposium officially begins this morning at 8:00 am San Francisco time, and will include well over 200 original presentations on prostate cancer alone.

Filed under: Uncategorized | Leave a Comment »

Outcomes-related data on prostate cancer patients followed for up to 43 years

Posted on March 4, 2010 by Sitemaster

Two papers to be presented by Lewinshtein and Porter at the Genitourinary Cancers Symposium (starting tomorrow in San Francisco) offer some interesting insights on patients initially treated as long ago as the mid-1950s.

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 3 Comments »

Cabazitaxel extends survival in Taxotere-refractory patients with CRPC

Posted on March 4, 2010 by Sitemaster

According to a media release from Sanofi-Aventis early this morning, the second-generation taxane cabazitaxel, when given in combination with prednisone, is capable of extending median survival by 2.4 months compared to mitoxantrone + prednisone in prostate cancer patients who are refractory to docetaxel (Taxotere) chemotherapy.

Filed under: Drugs in development | Tagged: , , , | 3 Comments »

Are multiple guidelines confusing men they are meant to help?

Posted on March 3, 2010 by Sitemaster

The following media release, referring to the new screening and early detection guidelines issued by the American Cancer Society, was distributed earlier today by Prostate Cancer International and other members of America’s Prostate Cancer Organizations:

Filed under: Diagnosis, Risk | Tagged: , , | 3 Comments »

ACS issues new prostate cancer screening guidelines

Posted on March 3, 2010 by Sitemaster

As of 10:00 am this morning Eastern Standard Time, the American Cancer Society issued the following media release about newly published guidelines on screening for prostate cancer. We have given this press release in full, without further comment at this time. The only addition to the press release is the direct link to the complete, [...]

Filed under: Diagnosis, Risk | Tagged: , , , | 3 Comments »

What the patients think … about RT + ADT

Posted on March 3, 2010 by Sitemaster

Well here’s a good idea! Let’s actually ask patients what they think about the pros and cons of long- and short-term hormone therapy in association with radiation!

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 6 Comments »

« Previous Page — Next Page »
Follow

Get every new post delivered to your Inbox.

Join 249 other followers